| Literature DB >> 34693252 |
Harsha S Nagarajarao1, Solomon K Musani2, Keith E Cobb3, James D Pollard2, Leroy L Cooper3, Anshul Anugu4, Yuichiro Yano5, Josiah A Moore6, Connie W Tsao7, Albert W Dreisbach2, Emelia J Benjamin8, Naomi M Hamburg8, Ramachandran S Vasan8, Gary F Mitchell9, Ervin R Fox2.
Abstract
RATIONALE &Entities:
Keywords: African Americans; Arterial stiffness; Chronic kidney disease; eGFR
Year: 2021 PMID: 34693252 PMCID: PMC8515070 DOI: 10.1016/j.xkme.2021.03.018
Source DB: PubMed Journal: Kidney Med ISSN: 2590-0595
Clinical Characteristics of Study Participants
| Characteristics | eGFR | Albuminuria | ||
|---|---|---|---|---|
| ≥60 mL/min/1.73m2 (n = 2,011) | 15-60 mL/min/1.73m2 (n = 233) | Absent (n = 2,012) | Present (n = 232) | |
| Age at tonometry visit, y | 65 ± 10 | 74 ± 9 | 66 ± 11 | 69 ± 11 |
| Female sex | 1,287 (64%) | 149 (64%) | 1,327 (66%) | 123 (53%) |
| Height, cm | 168 ± 9 | 167 ± 8 | 168 ± 9 | 170 ± 9 |
| Weight, kg | 89 ± 19 | 87 ± 17 | 88 ± 18 | 91 ± 20 |
| Body mass index, kg/m2 | 31.1 ± 6.1 | 31.1 ± 6.0 | 31.0 ± 6.0 | 31.8 ± 6.5 |
| Pressure, mm Hg | ||||
| Brachial systolic | 136 ± 18 | 144 ± 22 | 136 ± 18 | 146 ± 20 |
| Brachial diastolic | 72 ± 10 | 70 ± 11 | 72 ± 10 | 73 ± 11 |
| Cholesterol, mg/dL | ||||
| Fasting total | 198 ± 39 | 201 ± 47 | 198 ± 39 | 203 ± 48 |
| Fasting HDL cholesterol | 59 ± 16 | 58 ± 17 | 59 ± 16 | 57 ± 17 |
| Ratio of total to HDL cholesterol | 3.56 ± 1.06 | 3.72 ± 1.22 | 3.55 ± 1.06 | 3.75 ± 1.13 |
| LDL cholesterol | 120 ± 35 | 122 ± 44 | 120 ± 35 | 124 ± 42 |
| Fasting triglycerides, mg/dL | 84 [62, 113] | 95 [75, 128] | 84 [63, 113] | 96 [71, 133] |
| Fasting glucose, mg/dL | 105 ± 32 | 107 ± 32 | 103 ± 30 | 119 ± 43 |
| Concomitant disease and risk factors | ||||
| Diabetes mellitus | 563 (28%) | 91 (39%) | 543 (27%) | 111 (48%) |
| Antihypertensive medications | 402 (20%) | 75 (32%) | 382 (19%) | 88 (38%) |
| Antihyperlipidemic medications | 1,428 (71%) | 214 (92%) | 1,449 (72%) | 204 (88%) |
Note: Values expressed as mean ± standard deviation, number (percent), or median [interquartile range; 25th, 75th percentile]. Albuminuria is defined by urinary albumin-creatinine ratio > 25 mg/g in men and >35 mg/g in women on spot or 24-hour urine collection.
Abbreviations: eGHR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Vascular Function Characteristics of Study Participants
| Characteristics | eGFR | Albuminuria | ||
|---|---|---|---|---|
| ≥60 mL/min/1.73 m2 (n = 2,011 | 15-60 mL/min/1.73 m2 (n = 233 | Absent (n = 2,012 | Present (n = 232 | |
| Heart rate-tonometry, | 65 ± 10 | 74 ± 10 | 65 ± 10 | 66 ± 10 |
| Pulse wave velocity, | ||||
| Carotid-femoral | 10.9 ± 4.1 | 14.0 ± 5.2 | 10.9 ± 4.1 | 13.7 ± 5.2 |
| Carotid-brachial | 9.4 ± 2.1 | 9.8 ± 2.4 | 9.3 ± 2.1 | 10.1 ± 2.2 |
| Forward wave amplitude, mm Hg | 53 ± 15 | 63 ± 20 | 53 ± 16 | 62 ± 16 |
| Central pulse pressure, mm Hg | 65 ± 20 | 77 ± 24 | 65 ± 20 | 74 ± 21 |
| Mean arterial pressure, mm Hg | 99 ± 12 | 101 ± 13 | 99 ± 12 | 102 ± 13 |
| Characteristic impedance, | 266 ± 110 | 316 ± 113 | 266 ± 110 | 308 ± 121 |
| Brachial flow velocity, | ||||
| Baseline | 5.5 ± 3.2 | 4.8 ± 2.9 | 5.4 ± 3.2 | 5.1 ± 3.3 |
| Hyperemic | 47.8 ± 18.6 | 39.7 ± 16.6 | 47.5 ± 18.5 | 41.6 ± 18.1 |
Note: Values expressed as mean ± standard deviation. Albuminuria is defined by urinary albumin-creatinine ratio > 25 mg/g in men and >35 mg/g in women on spot or 24-hour urine collection.
Abbreviation: eGFR, estimated glomerular filtration rate.
Age- and Sex-Adjusted Associations of Vascular Function Measures With CKD, Albuminuria Status, and Urinary Albumin-Creatinine Ratio
| Predictor | CKD Stage 3-4 | Albuminuria | Urinary Albumin-Creatinine Ratio | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | % Change | ||||
| Hemodynamic parameters | ||||||
| Carotid-femoral pulse wave velocity | 1.48 (1.19 to 1.84) | <0.001 | 2.07 (1.68 to 2.57) | <0.001 | 25 (17 to 32) | <0.001 |
| Forward pressure wave amplitude | 1.30 (1.10 to 1.53) | 0.002 | 1.65 (1.38 to 1.97) | <0.001 | 23 (15 to 32) | <0.001 |
| Central pulse pressure | 1.28 (1.08 to 1.51) | 0.004 | 1.46 (1.24 to 1.70) | <0.001 | 19 (12 to 26) | <0.001 |
| Mean arterial pressure | 1.19 (1.01 to 1.39) | 0.03 | 1.43 (1.23 to 1.66) | <0.001 | 15 (9 to 22) | <0.001 |
| Characteristic impedance | 1.14 (0.97 to 1.33) | 0.11 | 1.36 (1.17 to 1.58) | <0.001 | 14 (7 to 21) | <0.001 |
| Brachial vascular reactivity parameters | ||||||
| Flow | ||||||
| Baseline | 0.96 (0.82 to 1.12) | 0.60 | 0.94 (0.81 to 1.09) | 0.43 | 1 (−3 to 6) | 0.66 |
| Hyperemic | 0.94 (0.79 to 1.12) | 0.51 | 0.79 (0.67 to 0.94) | 0.006 | −10 (−15 to −6) | <0.001 |
Note: Age standardized. Model parameters: measure adjusted for sex and age at tonometry visit.
Abbreviations: CKD, chronic kidney disease; OR, odds ratio.
Logistic regression.
Log transformed, linear regression.
Percent changes indicate change in carotid-femoral pulse wave velocity per incremental increase in log-transformed urinary albumin0creatinine ratio.
n = 1,702.
n = 2,244.
Multivariable-Adjusted Associations of Vascular Function Measures With CKD, Albuminuria Status, and Urinary Albumin-Creatinine Ratio
| Predictor | CKD Stage 3-4 | Albuminuria | Urinary Albumin-Creatinine Ratio | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | % Change (95% CI) | ||||
| Hemodynamic parameters | ||||||
| Carotid-femoral pulse wave velocity | 1.37 (1.08 to 1.75) | 0.01 | 1.66 (1.32 to 2.11) | <0.001 | 13 (6 to 21) | <0.001 |
| Forward pressure wave amplitude | 1.16 (0.96 to 1.40) | 0.13 | 1.37 (1.14 to 1.65) | 0.001 | 15 (8 to 23) | <0.001 |
| Central pulse pressure | 1.11 (0.90 to 1.37) | 0.33 | 1.28 (1.05 to 1.57) | 0.02 | 13 (5 to 21) | 0.001 |
| Mean arterial pressure | 1.18 (1.01 to 1.39) | 0.04 | 1.38 (1.19 to 1.61) | <0.001 | 13 (7 to 19) | <0.001 |
| Characteristic impedance | 1.06 (0.89 to 1.26) | 0.50 | 1.19 (1.00 to 1.40) | 0.04 | 6 (1 to 13) | 0.03 |
| Brachial vascular reactivity parameters | ||||||
| Flow | ||||||
| Baseline | 0.97 (0.82 to 1.14) | 0.71 | 0.88 (0.75 to 1.03) | 0.11 | −1 (−6 to 3) | 0.52 |
| Hyperemic | 1.00 (0.83 to 1.20) | 0.99 | 0.81 (0.68 to 0.95) | 0.01 | −10 (−14 to −5) | <0.001 |
Note: Age, triglyceride level, total cholesterol level, high-density lipoprotein cholesterol level, heart rate, and mean arterial pressure standardized. Model parameters: measure adjusted for sex, age at tonometry visit, triglyceride level, antihypertensive medications, total cholesterol level, high-density lipoprotein cholesterol level, diabetes mellitus status, antihyperlipidemic medications, antihypertensive medications, heart rate, and mean arterial pressure.
Abbreviations: CKD, chronic kidney disease; OR, odds ratio.
Logistic regression.
Log transformed, linear regression.
n = 1,702.
n = 2,244.
Figure 1Effect modification by diabetes on relation between carotid-femoral pulse wave velocity (PWV) and urinary albumin-creatinine ratio (UACR).
Figure 2Effect modification by sex on relation between forward wave amplitude and urinary albumin-creatinine ratio (UACR). Interaction P < 0.001. Model: measure adjusted for sex, age at tonometry visit, age squared, triglyceride level, antihypertensive medications, total cholesterol level, high-density lipoprotein cholesterol level, antihyperlipidemic medications, heart rate, and mean arterial pressure. Age, carotid femoral pulse wave velocity, triglyceride level, total cholesterol level, high-density lipoprotein cholesterol level, and mean pressure standardized.
Figure 3Effect modification by sex on relation between central pulse pressure and urinary albumin-creatinine ratio (UACR). Interaction P < 0.001. Model: measure adjusted for sex, age at tonometry visit, age squared, triglyceride level, antihypertensive medications, total cholesterol level, high-density lipoprotein cholesterol level, antihyperlipidemic medications, heart rate, and mean arterial pressure. Age, carotid femoral pulse wave velocity, triglyceride level, total cholesterol level, high-density lipoprotein cholesterol level, and mean pressure standardized.